

Endoscopy Data for Cancer

Lisa Galligan-Dawson, Phil Graham, Jenna Lane Chris Repper-Day

Context

- Endoscopy is crucial for the colorectal, OG and HPB cancer pathways, but GM has large backlogs (due in part to the pandemic).
- The existing cancer Patient Tracking List (PTL) does not include data on endoscopy procedures.
- This project will merge a new, GM-wide flow of endoscopy waiting list and activity data with the PTL data.
- The results will allow detailed analysis of the effects of endoscopy backlogs on cancer patients in GM, and to assess the impact of improvement projects.


Endoscopy waiting list

Endoscopy waiting list data has been sourced from the Waiting List Minimum Dataset (WLMDS, submitted weekly by trusts)




*Data w/c 4 September, note that numbers submitted by MFT may change following the HIVE migration.

Worked with trusts to have details of procedures included in all data.



Endoscopy for suspected cancer

For every upper and lower GI cancer pathway opened during January – June 2022, searched for an entry in the WLMDS for an endoscopy (matching based on pseudo-NHS number). Number of matches was lower than expected – the method may need to be reconsidered.



Endoscopy activity

- Weekly endoscopy activity at the individual (pseudonomised) patient level isn't currently reported by trusts.
- Designing a new data flow, working with GM Business
 Intelligence (BI). Data expected by December.
- Challenges due to competing national priorities on BI resources, e.g. virtual wards.

Capacity and demand for EUS

To reduce endoscopy backlogs we need to ensure we have enough capacity in the GM system. Currently modelling capacity and demand for EUS, a crucial diagnostic test for the OG and HPB pathways.

- Worked initially with one trust to model.
- Accounted for slots lost due to DNAs and cancellations. Considered capacity needed to meet 95th percentile of demand (enough capacity that there would be only 1 in
- 20 weeks where demand couldn't be met).
- Currently extending to all EUS providers in GM.
- Using historical referral data to predict future trends in EUS demand
- Challenges in gathering complex dataset from the trusts.

